Effect of phenytoin versus levetiracetam therapyon atracurium or vecuronium
Phase 4
Completed
- Conditions
- Health Condition 1: null- 1. ASA grade I or II undergoing neurosurgery under generalanesthesia.2. On chronic (7 days) phenytoin or levetiracetam therapy.
- Registration Number
- CTRI/2018/02/012190
- Lead Sponsor
- SCTIMST Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. ASA grade I or II undergoing neurosurgery under general
anesthesia.
2. Age 18-60 years, of either sex, who have the ability to give informed consent.
3. On chronic ( >7 days) phenytoin or levetiracetam therapy
Exclusion Criteria
1. Pre-existing neuromuscular disease
2. Prolonged administration of neuromuscular blocker
3. Any other drug known to affect neuromuscular function
4. Peripheral neuropathies
5. Prolonged immobility
6. Following major burns upto 2 years
7. Liver disease
8. Kidney disease
9. Cardiac disease
10. Pregnancy
11. Pre-existing or intraoperative acid-base disorder
12. Electrolyte imbalances such as hyper/hypokalemia, hyper/hypocalcemia,
hyper/hypomagnesemia, hyper/hyponatremia
13. Endocrinopathies
14. Patient refusal
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method